ARVINAS, INC. — Director's Dealing 2022

Jan 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARVINAS, INC. (ARVN)
CIK: 0001655759
Period of Report: 2021-12-30

Reporting Person: Peck Ronald (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-30	Common Stock	M	14375	$47.38	Acquired	19777	Direct
2021-12-30	Common Stock	M	5625	$26.58	Acquired	25402	Direct
2021-12-30	Common Stock	S	11371	$80.35	Disposed	14031	Direct
2021-12-30	Common Stock	S	8629	$80.96	Disposed	5402	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-30	Stock Option (right to buy)	$47.38	M	14375	Disposed	2030-02-26	Common Stock (14375)	Direct
2021-12-30	Stock Option (right to buy)	$26.58	M	5625	Disposed	2029-07-28	Common Stock (5625)	Direct

Footnotes

F1: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.

F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.76 to $80.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.515, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range set forth in this footnote.

F5: This option award was granted on February 27, 2020. 1/4 of the shares underlying the award vested on February 27, 2021, with the remainder of the shares vesting in equal monthly installments following February 27, 2021 through February 27, 2024.

F6: This option award was granted on July 29, 2019. 1/4 of the shares underlying the award vested on July 29, 2020, with the remainder of the shares vesting in equal monthly installments following July 29, 2020 through July 29, 2023.